person · Reporting owner

Harr Steve

Disclosed activity across 3 companies

Tapewire entity: 61688
SEC CIK: 0001627387

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Sana Biotechnology, Inc.SANA · Entity 4870	Director · President & CEO	March 06, 2026	March 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Sana Biotechnology, Inc.

Report date March 06, 2026 · Filed March 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	7,944,251	Ending reported balance After 2026-03-09 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2026-03-06 · Exercise / conversion · Acquired 41,666 · Balance 7,918,596 Row 2 · 2026-03-07 · Exercise / conversion · Acquired 50,000 · Balance 7,968,596 Row 3 · 2026-03-09 · Tax withholding · Disposed 11,526 · Balance 7,957,070 Row 4 · 2026-03-09 · Tax withholding · Disposed 12,819 · Balance 7,944,251
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	125,001	Reported balance After 2026-03-06 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-03-06 · Exercise / conversion · Disposed 41,666 · Balance 125,001 F2: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. F3: The award vested as to 25% of the restricted stock units on March 6, 2026, and the remaining restricted stock units will vest in three equal installments on each of March 6, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	100,000	Reported balance After 2026-03-07 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-03-07 · Exercise / conversion · Disposed 50,000 · Balance 100,000 F2: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. F4: The award vested as to 25% of the restricted stock units on each of March 7, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of March 7, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Common StockSEC Table I · non-derivative	IndirectHeld by Harr Family Irrevocable Trust of 2015 dtd 12/28/2015	682,500	Reported balance Holding disclosure · report date 2026-03-06 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 682,500
Common StockSEC Table I · non-derivative	IndirectHeld by Brian L Harr TTEE CCH Irrevocable Trust U/A DTD 03/25/2021	167,000	Reported balance Holding disclosure · report date 2026-03-06 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 167,000 F1: Brian L. Harr is the trustee of these trusts, whose sole beneficiaries are members of the reporting person's immediate family.
Common StockSEC Table I · non-derivative	IndirectHeld by Brian L Harr TTEE JOH Irrevocable Trust U/A DTD 03/25/2021	167,000	Reported balance Holding disclosure · report date 2026-03-06 · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · Balance 167,000 F1: Brian L. Harr is the trustee of these trusts, whose sole beneficiaries are members of the reporting person's immediate family.

Filing footnotes · ownership attribution and instrument terms

F1: Brian L. Harr is the trustee of these trusts, whose sole beneficiaries are members of the reporting person's immediate family.

F2: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.

F3: The award vested as to 25% of the restricted stock units on March 6, 2026, and the remaining restricted stock units will vest in three equal installments on each of March 6, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

F4: The award vested as to 25% of the restricted stock units on each of March 7, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of March 7, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Juno Therapeutics, Inc.

Report date March 05, 2018 · Filed March 07, 2018

Section 16 reporting ended · disclosed 2018-03-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2018-03-05 transaction · row 6 6 source rows · reconciled sequence Row 1 · 2018-03-05 · Other · Disposed 492,355 · Balance 147,162 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person, other than as described in notes (3) through (8) below, was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes. Row 2 · 2018-03-05 · Disposition to issuer · Disposed 50,010 · Balance 97,152 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F3: Represents time-based restricted stock awards ("RSAs"). F4: Pursuant to the Merger Agreement, these RSAs (the remaining unvested portions of which were fully accelerated under the Merger Agreement) were cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00. Row 3 · 2018-03-05 · Disposition to issuer · Disposed 20,580 · Balance 76,572 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F5: Represents shares of common stock of the Company underlying time-based restricted stock units ("RSUs"). F6: Pursuant to the Merger Agreement, the vested portion of such RSUs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSUs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSUs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock unit award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement). Row 4 · 2018-03-05 · Disposition to issuer · Disposed 29,135 · Balance 47,437 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F5: Represents shares of common stock of the Company underlying time-based restricted stock units ("RSUs"). F6: Pursuant to the Merger Agreement, the vested portion of such RSUs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSUs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSUs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock unit award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement). Row 5 · 2018-03-05 · Disposition to issuer · Disposed 11,544 · Balance 35,893 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F5: Represents shares of common stock of the Company underlying time-based restricted stock units ("RSUs"). F6: Pursuant to the Merger Agreement, the vested portion of such RSUs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSUs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSUs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock unit award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement). Row 6 · 2018-03-05 · Disposition to issuer · Disposed 35,893 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7: Represents performance-based restricted stock awards ("PSAs"). F8: Pursuant to the Merger Agreement, all PSAs will vest as to 50% of the total number of PSAs subject to such awards, and such vested portion will be cancelled and converted into a right to receive an amount in cash equal to the product of (i) such 50% vested portion of the award and (ii) the $87.00. The remaining 50% of the PSAs will be assumed by Parent, provided that the number of shares subject to such PSAs will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement) and the vesting will be adjusted such that (i) 60% of such remaining PSAs will vest on the one-year anniversary of the closing of the Merger and (ii) 40% of such remaining PSAs will vest on the earlier of (A) the second anniversary of the closing of the Merger and (B) the first approval by the U.S. Food and Drug Administration of JCAR017.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.72 · Expires 2024-11-13	Direct	Reported balance After 2018-03-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-03-05 · Disposition to issuer · Disposed 98,750 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F9: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement).
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.06 · Expires 2025-03-02	Direct	Reported balance After 2018-03-05 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-03-05 · Disposition to issuer · Disposed 85,000 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F9: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement).
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.50 · Expires 2026-02-01	Direct	Reported balance After 2018-03-05 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2018-03-05 · Disposition to issuer · Disposed 155,000 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F9: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement).
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.76 · Expires 2027-02-06	Direct	Reported balance After 2018-03-05 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2018-03-05 · Disposition to issuer · Disposed 127,841 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F9: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement).

Filing footnotes · ownership attribution and instrument terms

F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent.

F2: Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person, other than as described in notes (3) through (8) below, was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes.

F3: Represents time-based restricted stock awards ("RSAs").

F4: Pursuant to the Merger Agreement, these RSAs (the remaining unvested portions of which were fully accelerated under the Merger Agreement) were cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00.

F5: Represents shares of common stock of the Company underlying time-based restricted stock units ("RSUs").

F6: Pursuant to the Merger Agreement, the vested portion of such RSUs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSUs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSUs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock unit award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement).

F7: Represents performance-based restricted stock awards ("PSAs").

F8: Pursuant to the Merger Agreement, all PSAs will vest as to 50% of the total number of PSAs subject to such awards, and such vested portion will be cancelled and converted into a right to receive an amount in cash equal to the product of (i) such 50% vested portion of the award and (ii) the $87.00. The remaining 50% of the PSAs will be assumed by Parent, provided that the number of shares subject to such PSAs will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement) and the vesting will be adjusted such that (i) 60% of such remaining PSAs will vest on the one-year anniversary of the closing of the Merger and (ii) 40% of such remaining PSAs will vest on the earlier of (A) the second anniversary of the closing of the Merger and (B) the first approval by the U.S. Food and Drug Administration of JCAR017.

F9: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement).

Loxo Oncology, Inc.

Report date February 15, 2019 · Filed February 15, 2019

Section 16 reporting ended · disclosed 2019-02-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.66 · Expires 2026-11-06	Direct	Reported balance After 2019-02-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-02-15 · Disposition to issuer · Disposed 15,625 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.58 · Expires 2027-06-21	Direct	Reported balance After 2019-02-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-02-15 · Disposition to issuer · Disposed 11,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $180.98 · Expires 2028-06-12	Direct	Reported balance After 2019-02-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-02-15 · Disposition to issuer · Disposed 8,750 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 09, 2026 Filed Mar 10, 2026 16:16 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	Tax withholdingCommon Stock	12,819	$3.10	$39,738.90	Disclosure SEC source: 0001627387-26-000004 · primarydocument.xml · nonDerivative · entry 4 Harr Steve · CIK 0001627387 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,944,251 Read SEC document
March 09, 2026 Filed Mar 10, 2026 16:16 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	Tax withholdingCommon Stock	11,526	$3.13	$36,076.38	Disclosure SEC source: 0001627387-26-000004 · primarydocument.xml · nonDerivative · entry 3 Harr Steve · CIK 0001627387 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,957,070 Read SEC document
March 07, 2026 Filed Mar 10, 2026 16:16 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	Exercise / conversionRestricted Stock Units · Derivative	50,000	$0.00	$0.00	Disclosure SEC source: 0001627387-26-000004 · primarydocument.xml · derivative · entry 9 Harr Steve · CIK 0001627387 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. F4 · derivative.exercise_date: The award vested as to 25% of the restricted stock units on each of March 7, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of March 7, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. F4 · derivative.expiration_date: The award vested as to 25% of the restricted stock units on each of March 7, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of March 7, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document
March 07, 2026 Filed Mar 10, 2026 16:16 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	Exercise / conversionCommon Stock	50,000	$0.00	$0.00	Disclosure SEC source: 0001627387-26-000004 · primarydocument.xml · nonDerivative · entry 2 Harr Steve · CIK 0001627387 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,968,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 06, 2026 Filed Mar 10, 2026 16:16 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	Exercise / conversionRestricted Stock Units · Derivative	41,666	$0.00	$0.00	Disclosure SEC source: 0001627387-26-000004 · primarydocument.xml · derivative · entry 8 Harr Steve · CIK 0001627387 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,001 Underlying: Common Stock · 41,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. F3 · derivative.exercise_date: The award vested as to 25% of the restricted stock units on March 6, 2026, and the remaining restricted stock units will vest in three equal installments on each of March 6, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. F3 · derivative.expiration_date: The award vested as to 25% of the restricted stock units on March 6, 2026, and the remaining restricted stock units will vest in three equal installments on each of March 6, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document
March 06, 2026 Filed Mar 10, 2026 16:16 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	Exercise / conversionCommon Stock	41,666	$0.00	$0.00	Disclosure SEC source: 0001627387-26-000004 · primarydocument.xml · nonDerivative · entry 1 Harr Steve · CIK 0001627387 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,918,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 05, 2026 Filed Mar 6, 2026 16:52 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	GrantStock Option (Right to Buy) · Derivative	900,000	$0.00 Strike: $3.41	$0.00	Disclosure SEC source: 0001627387-26-000002 · primarydocument.xml · derivative · entry 2 Harr Steve · CIK 0001627387 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2036-03-04 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 5, 2027 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document
March 05, 2026 Filed Mar 6, 2026 16:52 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	GrantRestricted Stock Units · Derivative	200,000	$0.00	$0.00	Disclosure SEC source: 0001627387-26-000002 · primarydocument.xml · derivative · entry 1 Harr Steve · CIK 0001627387 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal installments on each of March 5, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. F2 · derivative.expiration_date: The restricted stock units vest in four equal installments on each of March 5, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document
March 10, 2025 Filed Mar 10, 2025 20:12 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	Tax withholdingCommon Stock	12,820	$2.56	$32,819.20	Disclosure SEC source: 0001562180-25-002271 · primarydocument.xml · nonDerivative · entry 2 Harr Steve · CIK 0001627387 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,876,930 Read SEC document
March 07, 2025 Filed Mar 10, 2025 20:12 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	Exercise / conversionRestricted Stock Units · Derivative	50,000	$0.00	$0.00	Disclosure SEC source: 0001562180-25-002271 · primarydocument.xml · derivative · entry 8 Harr Steve · CIK 0001627387 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. F5 · derivative.exercise_date: The award vested as to 25% of the restricted stock units on March 7, 2025 and the remaining restricted stock units will vest in three equal installments on each of March 7, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date. F5 · derivative.expiration_date: The award vested as to 25% of the restricted stock units on March 7, 2025 and the remaining restricted stock units will vest in three equal installments on each of March 7, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date. Read SEC document
March 07, 2025 Filed Mar 10, 2025 20:12 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	Exercise / conversionCommon Stock	50,000	$0.00	$0.00	Disclosure SEC source: 0001562180-25-002271 · primarydocument.xml · nonDerivative · entry 1 Harr Steve · CIK 0001627387 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,889,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 06, 2025 Filed Mar 10, 2025 20:12 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	GrantStock Option (Right to Buy) · Derivative	750,000	$0.00 Strike: $2.55	$0.00	Disclosure SEC source: 0001562180-25-002271 · primarydocument.xml · derivative · entry 7 Harr Steve · CIK 0001627387 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2035-03-05 F4 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 6, 2026 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document
March 06, 2025 Filed Mar 10, 2025 20:12 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	GrantRestricted Stock Units · Derivative	166,667	$0.00	$0.00	Disclosure SEC source: 0001562180-25-002271 · primarydocument.xml · derivative · entry 6 Harr Steve · CIK 0001627387 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,667 Underlying: Common Stock · 166,667 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal installments on each of March 6, 2026, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. F3 · derivative.expiration_date: The restricted stock units vest in four equal installments on each of March 6, 2026, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document
March 07, 2024 Filed Mar 8, 2024 16:18 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	GrantStock Option (Right to Buy) · Derivative	900,000	$0.00 Strike: $9.58	$0.00	Disclosure SEC source: 0001562180-24-002479 · primarydocument.xml · derivative · entry 2 Harr Steve · CIK 0001627387 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2034-03-06 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 7, 2025 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document
March 07, 2024 Filed Mar 8, 2024 16:18 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	GrantRestricted Stock Units · Derivative	200,000	$0.00	$0.00	Disclosure SEC source: 0001562180-24-002479 · primarydocument.xml · derivative · entry 1 Harr Steve · CIK 0001627387 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. F2 · derivative.expiration_date: The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document
March 02, 2023 Filed Mar 3, 2023 16:35 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	GrantStock Options (Right to Buy) · Derivative	650,000	$0.00 Strike: $3.76	$0.00	Disclosure SEC source: 0001562180-23-002397 · primarydocument.xml · derivative · entry 1 Harr Steve · CIK 0001627387 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2033-03-01 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 2, 2024 and in 36 equal monthly installments thereafter. Read SEC document
March 03, 2022 Filed Mar 8, 2022 09:08 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	GrantStock Options (Right to Buy) · Derivative	760,000	$0.00 Strike: $5.70	$0.00	Disclosure SEC source: 0001562180-22-002430 · primarydocument.xml · derivative · entry 1 Harr Steve · CIK 0001627387 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 760,000 Underlying: Common Stock · 760,000 shares Expires 2032-03-02 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 3, 2023 and in 36 equal monthly installments thereafter. Read SEC document
April 14, 2021 Filed Apr 15, 2022 19:14 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	GiftCommon Stock	167,000	$0.00	$0.00	Disclosure SEC source: 0001562180-22-003413 · primarydocument.xml · nonDerivative · entry 2 Harr Steve · CIK 0001627387 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,839,750 F1 · shares: On April 14, 2021 the Reporting Person transferred (i) 167,000 shares of common stock of the Issuer to the Brian L Harr TTEE CCH Irrevocable Trust U/A DTD 03/25/2021 (the "CCH Trust") and (ii) 167,000 shares of common stock of the Issuer to the Brian L Harr TTEE JOH Irrevocable Trust U/A DTD 03/25/2021 (the "JOH Trust" and, together with the CCH Trust, the "Harr Trusts"), of which Brian L. Harr is the trustee. Members of the Reporting Person's immediate family are the sole beneficiaries of each of the Harr Trusts. Read SEC document
April 14, 2021 Filed Apr 15, 2022 19:14 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	GiftCommon Stock	167,000	$0.00	$0.00	Disclosure SEC source: 0001562180-22-003413 · primarydocument.xml · nonDerivative · entry 1 Harr Steve · CIK 0001627387 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,006,750 F1 · shares: On April 14, 2021 the Reporting Person transferred (i) 167,000 shares of common stock of the Issuer to the Brian L Harr TTEE CCH Irrevocable Trust U/A DTD 03/25/2021 (the "CCH Trust") and (ii) 167,000 shares of common stock of the Issuer to the Brian L Harr TTEE JOH Irrevocable Trust U/A DTD 03/25/2021 (the "JOH Trust" and, together with the CCH Trust, the "Harr Trusts"), of which Brian L. Harr is the trustee. Members of the Reporting Person's immediate family are the sole beneficiaries of each of the Harr Trusts. Read SEC document
February 08, 2021 Filed Feb 10, 2021 18:53 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	ConversionSeries B Convertible Preferred Stock · Derivative	156,250	$0.00	$0.00	Disclosure SEC source: 0000899243-21-005738 · doc4.xml · derivative · entry 5 Harr Steve · CIK 0001627387 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 156,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering. F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. Read SEC document
February 08, 2021 Filed Feb 10, 2021 18:53 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	ConversionSeries A-2 Convertible Preferred Stock · Derivative	800,000	$0.00	$0.00	Disclosure SEC source: 0000899243-21-005738 · doc4.xml · derivative · entry 4 Harr Steve · CIK 0001627387 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 800,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering. F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. Read SEC document
February 08, 2021 Filed Feb 10, 2021 18:53 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	ConversionSeries A-1 Convertible Preferred Stock · Derivative	1,075,000	$0.00	$0.00	Disclosure SEC source: 0000899243-21-005738 · doc4.xml · derivative · entry 3 Harr Steve · CIK 0001627387 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,075,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering. F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. Read SEC document
February 08, 2021 Filed Feb 10, 2021 18:53 UTC	Sana Biotechnology, Inc. SANA · Entity 4870	ConversionCommon Stock	2,031,250	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-005738 · doc4.xml · nonDerivative · entry 1 Harr Steve · CIK 0001627387 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,173,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering. Read SEC document
February 15, 2019 Filed Feb 15, 2019 09:13 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	8,750	$235.00 Strike: $180.98	$2,056,250.00	Disclosure SEC source: 0001567619-19-004571 · doc1.xml · derivative · entry 3 Harr Steve · CIK 0001627387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,750 shares Expires 2028-06-12 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. Read SEC document
February 15, 2019 Filed Feb 15, 2019 09:13 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	11,000	$235.00 Strike: $78.58	$2,585,000.00	Disclosure SEC source: 0001567619-19-004571 · doc1.xml · derivative · entry 2 Harr Steve · CIK 0001627387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires 2027-06-21 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. Read SEC document
February 15, 2019 Filed Feb 15, 2019 09:13 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	15,625	$235.00 Strike: $19.66	$3,671,875.00	Disclosure SEC source: 0001567619-19-004571 · doc1.xml · derivative · entry 1 Harr Steve · CIK 0001627387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,625 shares Expires 2026-11-06 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. Read SEC document
June 13, 2018 Filed Jun 14, 2018 17:04 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	GrantDirector Stock Option (right to buy) · Derivative	8,750	$0.00 Strike: $180.98	$0.00	Disclosure SEC source: 0001140361-18-028641 · doc1.xml · derivative · entry 1 Harr Steve · CIK 0001627387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 8,750 shares Expires 2028-06-12 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning one month after the grant date, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document
March 05, 2018 Filed Mar 7, 2018 18:20 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	127,841	Not disclosed Strike: $20.76	Not disclosed	Disclosure SEC source: 0001209191-18-017812 · doc4.xml · derivative · entry 10 Harr Steve · CIK 0001627387 · CFO & Head, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 127,841 shares Expires 2027-02-06 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F9 · price: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). F9 · derivative.exercise_date: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). Read SEC document
March 05, 2018 Filed Mar 7, 2018 18:20 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	155,000	Not disclosed Strike: $24.50	Not disclosed	Disclosure SEC source: 0001209191-18-017812 · doc4.xml · derivative · entry 9 Harr Steve · CIK 0001627387 · CFO & Head, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 155,000 shares Expires 2026-02-01 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F9 · price: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). F9 · derivative.exercise_date: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). Read SEC document
March 05, 2018 Filed Mar 7, 2018 18:20 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	85,000	Not disclosed Strike: $48.06	Not disclosed	Disclosure SEC source: 0001209191-18-017812 · doc4.xml · derivative · entry 8 Harr Steve · CIK 0001627387 · CFO & Head, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,000 shares Expires 2025-03-02 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F9 · price: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). F9 · derivative.exercise_date: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). Read SEC document
March 05, 2018 Filed Mar 7, 2018 18:20 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	98,750	Not disclosed Strike: $8.72	Not disclosed	Disclosure SEC source: 0001209191-18-017812 · doc4.xml · derivative · entry 7 Harr Steve · CIK 0001627387 · CFO & Head, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 98,750 shares Expires 2024-11-13 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F9 · price: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). F9 · derivative.exercise_date: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). Read SEC document
March 05, 2018 Filed Mar 7, 2018 18:20 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	Disposition to issuerCommon Stock	35,893	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-017812 · doc4.xml · nonDerivative · entry 6 Harr Steve · CIK 0001627387 · CFO & Head, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7 · shares: Represents performance-based restricted stock awards ("PSAs"). F8 · price: Pursuant to the Merger Agreement, all PSAs will vest as to 50% of the total number of PSAs subject to such awards, and such vested portion will be cancelled and converted into a right to receive an amount in cash equal to the product of (i) such 50% vested portion of the award and (ii) the $87.00. The remaining 50% of the PSAs will be assumed by Parent, provided that the number of shares subject to such PSAs will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement) and the vesting will be adjusted such that (i) 60% of such remaining PSAs will vest on the one-year anniversary of the closing of the Merger and (ii) 40% of such remaining PSAs will vest on the earlier of (A) the second anniversary of the closing of the Merger and (B) the first approval by the U.S. Food and Drug Administration of JCAR017. Read SEC document
March 05, 2018 Filed Mar 7, 2018 18:20 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	Disposition to issuerCommon Stock	11,544	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-017812 · doc4.xml · nonDerivative · entry 5 Harr Steve · CIK 0001627387 · CFO & Head, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,893 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F5 · shares: Represents shares of common stock of the Company underlying time-based restricted stock units ("RSUs"). F6 · price: Pursuant to the Merger Agreement, the vested portion of such RSUs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSUs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSUs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock unit award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement). Read SEC document
March 05, 2018 Filed Mar 7, 2018 18:20 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	Disposition to issuerCommon Stock	29,135	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-017812 · doc4.xml · nonDerivative · entry 4 Harr Steve · CIK 0001627387 · CFO & Head, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,437 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F5 · shares: Represents shares of common stock of the Company underlying time-based restricted stock units ("RSUs"). F6 · price: Pursuant to the Merger Agreement, the vested portion of such RSUs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSUs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSUs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock unit award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement). Read SEC document
March 05, 2018 Filed Mar 7, 2018 18:20 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	Disposition to issuerCommon Stock	20,580	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-017812 · doc4.xml · nonDerivative · entry 3 Harr Steve · CIK 0001627387 · CFO & Head, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,572 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F5 · shares: Represents shares of common stock of the Company underlying time-based restricted stock units ("RSUs"). F6 · price: Pursuant to the Merger Agreement, the vested portion of such RSUs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSUs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSUs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock unit award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement). Read SEC document
March 05, 2018 Filed Mar 7, 2018 18:20 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	Disposition to issuerCommon Stock	50,010	$87.00	$4,350,870.00	Disclosure SEC source: 0001209191-18-017812 · doc4.xml · nonDerivative · entry 2 Harr Steve · CIK 0001627387 · CFO & Head, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,152 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F3 · shares: Represents time-based restricted stock awards ("RSAs"). F4 · price: Pursuant to the Merger Agreement, these RSAs (the remaining unvested portions of which were fully accelerated under the Merger Agreement) were cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00. Read SEC document
March 05, 2018 Filed Mar 7, 2018 18:20 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	OtherCommon Stock	492,355	$87.00	$42,834,885.00	Disclosure SEC source: 0001209191-18-017812 · doc4.xml · nonDerivative · entry 1 Harr Steve · CIK 0001627387 · CFO & Head, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,162 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2 · shares: Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person, other than as described in notes (3) through (8) below, was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes. Read SEC document
February 27, 2018 Filed Mar 1, 2018 18:23 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	GrantCommon Stock	11,544	$0.00	$0.00	Disclosure SEC source: 0001209191-18-015214 · doc4.xml · nonDerivative · entry 1 Harr Steve · CIK 0001627387 · CFO & Head, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 639,517 F1 · shares: Represents restricted stock units ("RSUs") granted pursuant to the 2014 Equity Incentive Plan. 25% of the RSUs vest on each anniversary of February 27, 2018. Read SEC document
February 07, 2018 Filed Feb 9, 2018 19:32 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	GiftCommon Stock	162,790	$0.00	$0.00	Disclosure SEC source: 0001209191-18-009016 · doc4.xml · nonDerivative · entry 2 Harr Steve · CIK 0001627387 · CFO & Head, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 627,973 F2 · price: Represents a bona fide gift of common stock; thus, there is no price associated with this transaction. Read SEC document
February 07, 2018 Filed Feb 9, 2018 19:32 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	Tax withholdingCommon Stock	1,704	$85.49	$145,674.96	Disclosure SEC source: 0001209191-18-009016 · doc4.xml · nonDerivative · entry 1 Harr Steve · CIK 0001627387 · CFO & Head, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 790,763 F1 · kind: Shares withheld by the issuer to satisfy tax withholding obligations on the vesting of restricted stock units. Read SEC document
January 31, 2018 Filed Feb 2, 2018 19:31 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	GrantCommon Stock	29,135	$0.00	$0.00	Disclosure SEC source: 0001209191-18-007213 · doc4.xml · nonDerivative · entry 1 Harr Steve · CIK 0001627387 · CFO & Head, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 792,467 F1 · shares: Represents restricted stock units ("RSUs") granted pursuant to the 2014 Equity Incentive Plan. 25% of the RSUs vest on each anniversary of January 31, 2018. Read SEC document
December 21, 2017 Filed Dec 22, 2017 16:59 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	Exercise / conversionStock Option (Right to Buy) · Derivative	8,750	$0.00 Strike: $8.72	$0.00	Disclosure SEC source: 0001209191-17-067087 · doc4.xml · derivative · entry 4 Harr Steve · CIK 0001627387 · CFO & Head, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,750 Underlying: Common Stock · 8,750 shares Expires 2024-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to the option vested and became exercisable on December 14, 2014 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document
December 21, 2017 Filed Dec 22, 2017 16:59 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	SaleCommon Stock	500	$45.18	$22,591.00	Disclosure SEC source: 0001209191-17-067087 · doc4.xml · nonDerivative · entry 3 Harr Steve · CIK 0001627387 · CFO & Head, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 763,332 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2014, as amended March 24, 2015. F3 · price: This transaction was executed in multiple trades at prices ranging from $45.15 to $45.21. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
December 21, 2017 Filed Dec 22, 2017 16:59 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	SaleCommon Stock	8,250	$44.74	$369,082.73	Disclosure SEC source: 0001209191-17-067087 · doc4.xml · nonDerivative · entry 2 Harr Steve · CIK 0001627387 · CFO & Head, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 763,832 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2014, as amended March 24, 2015. F2 · price: This transaction was executed in multiple trades at prices ranging from $44.15 to $45.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
December 21, 2017 Filed Dec 22, 2017 16:59 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	Exercise / conversionCommon Stock	8,750	$8.72	$76,300.00	Disclosure SEC source: 0001209191-17-067087 · doc4.xml · nonDerivative · entry 1 Harr Steve · CIK 0001627387 · CFO & Head, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 772,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 20, 2017 Filed Oct 20, 2017 20:27 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	GrantCommon Stock	35,893	$0.00	$0.00	Disclosure SEC source: 0001209191-17-057695 · doc4.xml · nonDerivative · entry 1 Harr Steve · CIK 0001627387 · CFO & Head, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 763,332 F1 · shares: Represents restricted stock awards ("RSAs") granted pursuant to the 2014 Equity Incentive Plan. The RSAs will become eligible to vest based on the achievement of certain performance goals as follows, subject to the reporting person remaining a service provider to the Issuer through the applicable vesting date: Up to 21,535 shares will become eligible to vest based on the first approval by the U.S. Food & Drug Administration (the "FDA") of JCAR017 in any indication within certain designated timeframes (the "JCAR017 Milestone"). 50% of the shares that become eligible to vest upon the achievement of the JCAR017 Milestone will vest immediately upon such achievement. The remaining 50% of shares that become eligible to vest upon the achievement of the JCAR017 Milestone will vest on the one year anniversary of the date of such achievement. Up to 14,358 shares will vest based upon the first approval by the FDA of JCARH125 in any indication within certain designated timeframes. Read SEC document
July 03, 2017 Filed Jul 5, 2017 18:41 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	Exercise / conversionStock Option (Right to Buy) · Derivative	8,750	$0.00 Strike: $8.72	$0.00	Disclosure SEC source: 0001209191-17-043695 · doc4.xml · derivative · entry 3 Harr Steve · CIK 0001627387 · CFO & Head, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,500 Underlying: Common Stock · 8,750 shares Expires 2024-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48th of the shares subject to the option vested and became exercisable on December 14, 2014 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document
July 03, 2017 Filed Jul 5, 2017 18:41 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	SaleCommon Stock	8,750	$30.00	$262,500.00	Disclosure SEC source: 0001209191-17-043695 · doc4.xml · nonDerivative · entry 2 Harr Steve · CIK 0001627387 · CFO & Head, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 727,439 F1 · price: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2014, as amended March 24, 2015. Read SEC document
July 03, 2017 Filed Jul 5, 2017 18:41 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	Exercise / conversionCommon Stock	8,750	$8.72	$76,300.00	Disclosure SEC source: 0001209191-17-043695 · doc4.xml · nonDerivative · entry 1 Harr Steve · CIK 0001627387 · CFO & Head, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 736,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 27, 2017 Filed Jun 29, 2017 19:43 UTC	Juno Therapeutics, Inc. JUNO · Entity 168572	Exercise / conversionStock Option (Right to Buy) · Derivative	8,750	$0.00 Strike: $8.72	$0.00	Disclosure SEC source: 0001209191-17-042396 · doc4.xml · derivative · entry 3 Harr Steve · CIK 0001627387 · CFO & Head, Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,250 Underlying: Common Stock · 8,750 shares Expires 2024-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48th of the shares subject to the option vested and became exercisable on December 14, 2014 and 1/48th of the shares subject to the option shall vest monthly thereafter. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.